Literature DB >> 2049464

Coincidence of acquired factor-X deficiency and disseminated intravascular coagulation in patients with acute nonlymphoblastic leukemia.

I Pabinger1, P Bettelheim, R Dudczak, W Hinterberger, P A Kyrle, H Niessner, I Schwarzinger, W Speiser, K Lechner.   

Abstract

Systematic clotting studies were performed in 157 patients with de novo acute nonlymphoblastic leukemia (ANLL) prior to treatment. Sixteen patients had disseminated intravascular coagulation (DIC). Three of the patients with DIC (two with M3, one with M5 leukemia) had a marked isolated factor-X deficiency (factor X:C 21%, 33%, and 41%, respectively). Another four patients had a mild isolated factor-X deficiency (factor X:C 55%-68%). In these seven patients the remaining liver-synthesized clotting factors (factors II, VII, IX, V) as well as serum albumin and cholinesterase were within the normal range. Liver disease or vitamin-K deficiency could therefore be excluded. In none of the 141 patients without DIC was a marked isolated factor X deficiency observed; two patients had moderately reduced factor X:C levels but normal liver-synthesized proteins. Induction treatment led to the control of DIC with an almost parallel increase of fibrinogen and factor X up to normal in all patients with factor-X deficiency who achieved complete remission. In one patient, recurrence of leukemia was associated with reoccurrence of DIC and marked factor-X deficiency. We conclude that there is a coincidence of isolated factor-X deficiency and DIC in some patients with ANLL. In some patients, this factor-X deficiency may be severe enough to contribute to the bleeding tendency.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2049464     DOI: 10.1007/bf01703144

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  34 in total

1.  ACUTE PROMYELOCYTIC LEUKEMIA WITH FIBRINOGEN AND FACTOR V DEFICIENCIES.

Authors:  P DIDISHEIM; J S TROMBOLD; L E VANDERVOORT; R S MIBASHAN
Journal:  Blood       Date:  1964-06       Impact factor: 22.113

2.  Acute promyelocytic leukemia associated with hypofibrinogenemia.

Authors:  R L ROSENTHAL
Journal:  Blood       Date:  1963-04       Impact factor: 22.113

3.  Acute promyelocytic leukaemia: haemorrhagic manifestation and morphologic criteria.

Authors:  H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1975-03       Impact factor: 6.998

4.  Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia.

Authors:  G Avvisati; J W ten Cate; A Sturk; R Lamping; M G Petti; F Mandelli
Journal:  Br J Haematol       Date:  1988-09       Impact factor: 6.998

5.  Intravascular coagulation in acute leukemia: clinical and subclinical abnormalities.

Authors:  H R Gralnick; S Marchesi; H Givelber
Journal:  Blood       Date:  1972-11       Impact factor: 22.113

6.  Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency.

Authors:  B S Schwartz; E C Williams; M G Conlan; D F Mosher
Journal:  Ann Intern Med       Date:  1986-12       Impact factor: 25.391

7.  Combinations of increased thrombin, plasmin and non-specific protease activity in patients with acute leukaemia.

Authors:  M J Galloway; M J Mackie; B A McVerry
Journal:  Haemostasis       Date:  1983

8.  Prophylactic heparin therapy in acute promyelocytic leukemia.

Authors:  R L Drapkin; T S Gee; M D Dowling; Z Arlin; S McKenzie; S Kempin; B Clarkson
Journal:  Cancer       Date:  1978-06       Impact factor: 6.860

9.  A factor X-activating cysteine protease from malignant tissue.

Authors:  S G Gordon; B A Cross
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

10.  Acute promyelocytic leukemia--clinical management of 15 patients.

Authors:  P A Daly; C A Schiffer; P H Wiernik
Journal:  Am J Hematol       Date:  1980       Impact factor: 10.047

View more
  1 in total

1.  Acquired factor X deficiency and disseminated intravascular coagulation in a case of metastasizing carcinoma of the stomach and its course under chemotherapy.

Authors:  W Korte; R Flury
Journal:  Ann Hematol       Date:  1992-03       Impact factor: 3.673

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.